İstanbul Journal of Pharmacy

GÖNDERBİLGİ
EnglishTürkçe

Araştırma Makalesi


DOI :10.26650/IstanbulJPharm.2019.19036   IUP :10.26650/IstanbulJPharm.2019.19036    Tam Metin (PDF)

Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design

Yılmaz Çapan, Seçil Çaban Toktaş, Adem Şahin, Hayrettin Tonbul, Fırat Yerlikaya, Yeşim Aktaş

Nano drug co-delivery system is a popular strategy for combined application of two or more anticancer and/or synergistic drugs. Synergistic effects of nonsteroidal anti-inflammatory drugs and anti-cancer drugs in cancer treatment are shown in the literature. This study aimed to screen and understand the critical formulation and process parameters in the preparation of flurbiprofen and paclitaxel co-loaded nanoparticles to develop an anti-cancer nano co-delivery system. With this aim, critical parameters were determined using the Plackett–Burman experimental design (DoE). Flurbiprofen and paclitaxel drug loading amounts were considered as critical quality attributes to control the effective drug loading ratio. Furthermore, average particle size and zeta potential were also defined as critical quality attributes in order to optimize passive drug targeting and colloidal stability. Surfactant type was determined as the most significant factor for the average particle size and zeta potential. For flurbiprofen and paclitaxel drug loading into the nanoparticles, amounts of both flurbiprofen and paclitaxel were determined as critical factors. Consequently, paclitaxel and flurbiprofen were efficiently loaded into nanoparticles, and the impact of the formulation variables was successfully screened by a DoE. By controlling the determined parameters, the therapeutic efficacy of co-loaded drug nanoparticles could be maximized in further studies.

Anahtar Kelimeler: Nanoparticles, paclitaxel, flurbiprofen, PLGA, design of experiments, Plackett–Burman

PDF Görünüm

Referanslar

  • Acharya S, Sahoo SK (2011). PLGA nanoparticles containing various anticancer agents and tumour delivery by EPR effect. Adv Drug Deliv Rev 63: 170-183. google scholar
  • Collnot EM, Baldes C, Schaefer UF, Edgar KJ, Wempe MF, Lehr CM (2010). Vitamin E TPGS P-glycoprotein inhibition mechanism: influence on conformational flexibility, intracellular ATP levels, and role of time and site of access. Mol Pharm 7: 642-651. google scholar
  • Danhier F, Ansorena E, Silva JM, Coco R, Le Breton A, Preat V (2012). PLGA-based nanoparticles: an overview of biomedical applications. J Control Release 161: 505-522. google scholar
  • Dinarvand R, Sepehri N, Manoochehri S, Rouhani H, Atyabi F (2011). Polylactide-co-glycolide nanoparticles for controlled delivery of anticancer agents. Int J Nanomedicine 6: 877-895. google scholar
  • Gaonkar RH, Ganguly S, Dewanjee S, Sinha S, Gupta A, Ganguly S, Chatterjee Debnath M (2017). Garcinol loaded vitamin E TPGS emulsified PLGA nanoparticles: preparation, physicochemical characterization, in vitro and in vivo studies. Sci Rep 530: 1-14. google scholar
  • Hillaireau H, Couvreur P (2009). Nanocarriers’ entry into the cell: relevance to drug delivery. Cell Mol Life Sci 66: 2873-2896. google scholar
  • Jin H, Wang Z, Liu L, Gao L, Sun L, Li X, Fan D (2010). R-flurbiprofen reverses multidrug resistance, proliferation and metastasis in gastric cancer cells by p75(NTR) induction. Mol Pharm 7: 156-168. google scholar
  • Kozlu S, Sahin A, Ultav G, Yerlikaya F, Calis S, Capan Y. (2018). Development and in vitro evaluation of doxorubicin and celecoxib co-loaded bone targeted nanoparticles. J Drug Deliv Sci Technol 45: 213-219. google scholar
  • Liu JK, Patel SK, Gillespie DL, Whang K, Couldwell WT (2012). R-flurbiprofen, a novel nonsteroidal anti-inflammatory drug, decreases cell proliferation and induces apoptosis in pituitary adenoma cells in vitro. J Neurooncol 106: 561-569. google scholar
  • Ma P, Mumper RJ (2013). Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol 4: 1000164. google scholar
  • Malvern. Zeta Potential An Introduction in 30 Minutes Retrieved from https://www.materials-talks.com/wp-content/uploads/2017/09/mrk654-01_an_introduction_to_zeta_potential_v3.pdf google scholar
  • Ostolska I, Wiśniewska M (2014). Application of the zeta potential measurements to explanation of colloidal Cr(2)O(3) stability mechanism in the presence of the ionic polyamino acids. Colloid Polym Sci 292: 2453-2464. google scholar
  • Qi SS, Sun JH, Yu HH, Yu SQ (2017). Co-delivery nanoparticles of anti-cancer drugs for improving chemotherapy efficacy. Drug Deliv 24: 1909-1926. google scholar
  • Rahman Z, Zidan AS, Habib MJ, Khan MA (2010a). Understanding the quality of protein loaded PLGA nanoparticles variability by Plackett-Burman design. Int J Pharm 389: 186-194. google scholar
  • Saadati R, Dadashzadeh S (2014). Marked effects of combined TPGS and PVA emulsifiers in the fabrication of etoposide-loaded PLGA-PEG nanoparticles: in vitro and in vivo evaluation. Int J Pharm 464: 135-144. google scholar
  • Sahin A, Esendagli G, Yerlikaya F, Caban-Toktas S, Yoyen-Ermis D, Horzum U, Capan Y (2017a). A small variation in average particle size of PLGA nanoparticles prepared by nanoprecipitation leads to considerable change in nanoparticles’ characteristics and efficacy of intracellular delivery. Artif Cells Nanomed Biotechnol 45: 1657-1664. google scholar
  • Sahin A, Spiroux F, Guedon I, Arslan FB, Sarcan ET, Ozkan T, Capan Y (2017b). Using PVA and TPGS as combined emulsifier in nanoprecipitation method improves characteristics and anticancer activity of ibuprofen loaded PLGA nanoparticles. Pharmazie 72: 525-528. google scholar
  • Thun MJ, Henley SJ, Patrono C (2002). Nonsteroidal anti-inflammatory drugs as anticancer agents: mechanistic, pharmacologic, and clinical issues. J Natl Cancer Inst 94: 252-266. google scholar
  • Warsi MH, Anwar M, Garg V, Jain GK, Talegaonkar S, Ahmad FJ, Khar RK (2014). Dorzolamide-loaded PLGA/vitamin E TPGS nanoparticles for glaucoma therapy: Pharmacoscintigraphy study and evaluation of extended ocular hypotensive effect in rabbits. Colloids Surf B Biointerfaces 122: 423-431. google scholar
  • Wicki A, Witzigmann D, Balasubramanian V, Huwyler J (2015). Nanomedicine in cancer therapy: challenges, opportunities, and clinical applications. J Control Release 200: 138-157. google scholar
  • Win KY, Feng SS (2006). In vitro and in vivo studies on vitamin E TPGS-emulsified poly(d,l-lactic-co-glycolic acid) nanoparticles for paclitaxel formulation. Biomaterials 27: 2285-2291. google scholar
  • Yang C, Wu T, Qi Y, Zhang Z (2018). Recent Advances in the Application of Vitamin E TPGS for Drug Delivery. Theranostics 8: 464-485. google scholar
  • Yerlikaya F, Ozgen A, Vural I, Guven O, Karaagaoglu E, Khan MA, Capan Y (2013). Development and evaluation of paclitaxel nanoparticles using a quality-by-design approach. J Pharm Sci 102: 3748-3761. google scholar
  • Yu LX, Amidon G, Khan MA, Hoag SW, Polli J, Raju GK, Woodcock J (2014). Understanding pharmaceutical quality by design. AAPS J 16: 771-783. google scholar
  • Zhang Z, Tan S, Feng SS (2012). Vitamin E TPGS as a molecular biomaterial for drug delivery. Biomaterials 33: 4889-4906. google scholar
  • Zhu H, Chen H, Zeng X, Wang Z, Zhang X, Wu Y, Feng SS (2014). Co-delivery of chemotherapeutic drugs with vitamin E TPGS by porous PLGA nanoparticles for enhanced chemotherapy against multi-drug resistance. Biomaterials 35: 2391-2400. google scholar

Atıflar

Biçimlendirilmiş bir atıfı kopyalayıp yapıştırın veya seçtiğiniz biçimde dışa aktarmak için seçeneklerden birini kullanın


DIŞA AKTAR



APA

Çapan, Y., Çaban Toktaş, S., Şahin, A., Tonbul, H., Yerlikaya, F., & Aktaş, Y. (0001). Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design. İstanbul Journal of Pharmacy, 49(3), 161-166. https://doi.org/10.26650/IstanbulJPharm.2019.19036


AMA

Çapan Y, Çaban Toktaş S, Şahin A, Tonbul H, Yerlikaya F, Aktaş Y. Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design. İstanbul Journal of Pharmacy. 0001;49(3):161-166. https://doi.org/10.26650/IstanbulJPharm.2019.19036


ABNT

Çapan, Y.; Çaban Toktaş, S.; Şahin, A.; Tonbul, H.; Yerlikaya, F.; Aktaş, Y. Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design. İstanbul Journal of Pharmacy, [Publisher Location], v. 49, n. 3, p. 161-166, 0001.


Chicago: Author-Date Style

Çapan, Yılmaz, and Seçil Çaban Toktaş and Adem Şahin and Hayrettin Tonbul and Fırat Yerlikaya and Yeşim Aktaş. 0001. “Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design.” İstanbul Journal of Pharmacy 49, no. 3: 161-166. https://doi.org/10.26650/IstanbulJPharm.2019.19036


Chicago: Humanities Style

Çapan, Yılmaz, and Seçil Çaban Toktaş and Adem Şahin and Hayrettin Tonbul and Fırat Yerlikaya and Yeşim Aktaş. “Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design.” İstanbul Journal of Pharmacy 49, no. 3 (Nov. 2024): 161-166. https://doi.org/10.26650/IstanbulJPharm.2019.19036


Harvard: Australian Style

Çapan, Y & Çaban Toktaş, S & Şahin, A & Tonbul, H & Yerlikaya, F & Aktaş, Y 0001, 'Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design', İstanbul Journal of Pharmacy, vol. 49, no. 3, pp. 161-166, viewed 15 Nov. 2024, https://doi.org/10.26650/IstanbulJPharm.2019.19036


Harvard: Author-Date Style

Çapan, Y. and Çaban Toktaş, S. and Şahin, A. and Tonbul, H. and Yerlikaya, F. and Aktaş, Y. (0001) ‘Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design’, İstanbul Journal of Pharmacy, 49(3), pp. 161-166. https://doi.org/10.26650/IstanbulJPharm.2019.19036 (15 Nov. 2024).


MLA

Çapan, Yılmaz, and Seçil Çaban Toktaş and Adem Şahin and Hayrettin Tonbul and Fırat Yerlikaya and Yeşim Aktaş. “Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design.” İstanbul Journal of Pharmacy, vol. 49, no. 3, 0001, pp. 161-166. [Database Container], https://doi.org/10.26650/IstanbulJPharm.2019.19036


Vancouver

Çapan Y, Çaban Toktaş S, Şahin A, Tonbul H, Yerlikaya F, Aktaş Y. Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design. İstanbul Journal of Pharmacy [Internet]. 15 Nov. 2024 [cited 15 Nov. 2024];49(3):161-166. Available from: https://doi.org/10.26650/IstanbulJPharm.2019.19036 doi: 10.26650/IstanbulJPharm.2019.19036


ISNAD

Çapan, Yılmaz - Çaban Toktaş, Seçil - Şahin, Adem - Tonbul, Hayrettin - Yerlikaya, Fırat - Aktaş, Yeşim. “Development of paclitaxel and flurbiprofen coloaded PLGA nanoparticles: understanding critical formulation and process parameters using Plackett– Burman design”. İstanbul Journal of Pharmacy 49/3 (Nov. 2024): 161-166. https://doi.org/10.26650/IstanbulJPharm.2019.19036



ZAMAN ÇİZELGESİ


Kabul10.09.2019

LİSANS


Attribution ShareAlike (CC BY-SA)

This license lets others remix, tweak, and build upon your work even for commercial purposes, as long as they credit you and license their new creations under the identical terms. This license is often compared to “copyleft” free and open source software licenses. All new works based on yours will carry the same license, so any derivatives will also allow commercial use. This is the license used by Wikipedia, and is recommended for materials that would benefit from incorporating content from Wikipedia and similarly licensed projects.


PAYLAŞ




İstanbul Üniversitesi Yayınları, uluslararası yayıncılık standartları ve etiğine uygun olarak, yüksek kalitede bilimsel dergi ve kitapların yayınlanmasıyla giderek artan bilimsel bilginin yayılmasına katkıda bulunmayı amaçlamaktadır. İstanbul Üniversitesi Yayınları açık erişimli, ticari olmayan, bilimsel yayıncılığı takip etmektedir.